Knowledge of Diabetes mellitus-HIV Co-Infection Among Health Care Workers in Primary And Secondary Health Facilities in Osun State, South West Nigeria


  • FARINLOYE Emmanuel Oludele
  • ADELEKE Najemdeen Ajao
  • ADEBIMPE Wasiu Olalekan
  • ABIODUN Omoniyi Moses


Advent of drug combinations in Highly Active Antiretroviral Therapy (HAART) has been a major achievement in the management of HIV/AIDS. However, some of the drugs involved e.g. protease inhibitors have as side effects metabolic disorders like diabetes mellitus DM and dyslipidemia due to affectation of the pancreas and other organs. A cross-sectional study to determine the knowledge of health care workers on DM, HIV and how some of the drugs used in treating HIV infection secondarily cause metabolic disease like DM. Self-administered, pre-tested questionnaires were distributed to 279 health workers from the primary and secondary health care facilities in Osun state attending state wide workshops on GDM organised by Strategy for Improving Diabetes Care in Nigeria (SIDCAIN) team. Two thirds (66.2%) of the respondents had good knowledge on DM, while about three quarters (76.3%) had good knowledge on HIV. Only about a third (32.4%) of all respondents had good knowledge on effects of drugs management of HIV on DM. Health care providers have poor knowledge of HAART induced DM. Regular update workshops are therefore recommended for such awareness.


Adamu G Bakari, Fatima San9-Bello, Mohammed S Shehu, Ahmed Mai, Ibrahim S Aliyu, Ibrahim L Lawal. Antiretroviral therapy induced diabetes in a Nigerian. Afr Health Sci. Sep 2007;7(3) : 133- 135

Adeleke et al (2014) Management of gestational diabetes mellitus at secondary health care level: a survey of ante- natal care givers’ knowledge, attitude and practice. Res. J. Of Health Sci. 2(2),79-89.

Andeel A Butt, Kathleen McGinnis, Maria C Rodriguez – Barradas, et al. HIV infection and the Risk of Diabetes Mellitus AIDS. 2009 June 19; 23(10): 1222- 1234.

Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of DM in the multicentre AIDS cohort study. Arch Intern Med 2005;165: 1179- 1184

Bruno Ledergerber, Hansjakob Furrer, Martin Rickenbach, et al. Factors associated with the Incidence of Type 2 Diabetes Mellitus in HIV-infected participants in the Swiss HIV Cohort study. Clin Infec Dis.(2007);45(1):111-119.

Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperglycaemia in patients receiving HIV protease inhibitors. AIDs. 1998; 12: F51- F58

Christine A Hughes, Richard P Cashin, Dean T Eurich, Stan Houston. Risk factors for new – onset diabetes mellitus in patients receiving Protease Inhibitor therapy. Can J Infec Dis Med Microbiol. 2005 Jul – Aug; 16(4): 230 -232.

Heath KV, Montaner JS, Bondy G, Singer J, O'Shaughnessy MV, Hogg RS.2003. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets. 2003 Jan;4(1):13-22

IDF. Diabetes atlas (4th edn). Brussels: International Diabetes Federation, 2009.

Jean Claude N Mbanya, Ayesha A Motala, Eugene Sobngwi, Felix K Assah, Sostanie T Enoru (2010) Diabetes in sub-Saharan Africa Lancet 2010; 375: 2254–66

Jinqi AM, Nansseu JR, Noubiap JJ. Primary care Physicians’practice regarding diabetes mellitus diagnosis, evaluation and management in the west region Cameroon. BMC Endocr Disord. 2015 April 4;15:18

Justman JE, Benning L, Danoff N, et al. Protease inhibitor use and the incidence of DM in a large cohort of HIV infected women. J Acquir Immune Defic Sybdr 2003;32: 298 – 302.

Kino T, Mirani M, Alesci S, Chrousos GP. AIDs related lipodystrophy/insulin resistance syndrome. Horm Metab Res. 2003; 35: 129 – 136

Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.

Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001; 135: 17 – 26

Ruud KW, Srinivas SC, Toverud EL. Knowledge of HIV and its treatment among health care providers in South Africa. Int J Clin Pharm. 2014 Apr, 36(2) : 352 – 9.

Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother. Dec 2000;44(12):3451-3455.

Shresta M, Maharjon R, Prajapati A, Ghimire S, Shrestha N, Banstola A. Assessment of knowledge and practice of community pharmacy personnel on diabetes mellitus management in Kathmandu district: a cross sectional descriptive study. J Diabet Metab Disord. 2015; 14:71

WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic update and health sector progress towards universal access 2011. Geneva: WHO, 2011.






Original Articles